Hemocompatibility of Membranes for Double Filtration Lipoprotein Apheresis

Hemocompatibility of Membranes for Double Filtration Lipoprotein Apheresis - Hemocompatibility of LPA Membranes

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

DRKS

Registry ID

DRKS00014075

Enrollment

Registered

2018-04-25

Start date

2018-03-22

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

severe lipid disorders E78

Interventions

Group 1: Single application of Polyethersulfone-Poylvinylpyrrolidone membranes for double filtration lipoprotein apheresis Group 2: Single application of Ethylene-Vinyl-Alcohol membranes for double fi

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Age = 18 years; lipometabolic disorder requiring lipoprotein apheresis; routinely scheduled double filtration lipoprotein apheresis; Hematocrit = 37 %; stable anticoagulation regimen for apheresis; no ongoing infection; signed informed consent form

Exclusion criteria

Exclusion criteria: Inclusion criteria not met; known HIV or hepatitis B or C infection; pregnancy; unstable clinical condition (e.g. cardiac or vascular instability); known coagulation problems; patients participating in another study interfering with the planned trial

Design outcomes

Primary

Measure	Time frame
White blood cell counts and complement factor C5a plasma level at baseline and during the treatment after 5, 10, 15, 20, 25 und 30 min as well as at the end	—

Secondary

Measure	Time frame
Thrombin-antithrombin-III plasma level; platelet count, CD62L, and CD62P in blood at baseline and during the treatment after 30 min and at the end	—

Countries

Germany

Contacts

Public ContactDetlef Krieter

Universitätsklinik Würzburg, Nephrologie

krieter_d@ukw.de0931-20139300

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026